All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing the key results from a phase I/II trial investigating the combination of azacitidine, venetoclax, and magrolimab for the treatment of patients with newly diagnosed or relapsed/refractory acute myeloid leukemia. These data were recently presented by Naval Daver at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition and offers a rationale for further investigation of magrolimab within triplet combination therapy for patients with acute myeloid leukemia.
To download this visual abstract, click below.Download here
What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
During the 64th ASH Annual Meeting and Exposition, the AML Hub was pleased to speak to Courtney DiNardo, MD Anderson Cancer Center, Houston, US....
Staying on track in a rapidly changing treatment landscape
Interview with Eunice Wang, Roswell Park Comprehensive Cancer Center, about the rapidly changing treatment landscape for patients with AML.
Subscribe to get the best content related to AML delivered to your inbox